imvigor210_pdata: IMvigor210 Bladder Cancer Immunotherapy Cohort Data

In IOBR: Immune Oncology Biological Research

IMvigor210 Bladder Cancer Immunotherapy Cohort Data

Description

Clinical and biomarker data from the IMvigor210 clinical trial cohort. Includes treatment response, survival outcomes, and immune biomarker measurements for bladder cancer patients treated with atezolizumab.

Usage

data(imvigor210_pdata)

Format

A data frame with patients as rows and variables as columns:

ID

Patient sample identifier

BOR

Best overall response (CR, PR, SD, PD, NA)

BOR_binary

Binary response classification (R=responder, NR=non-responder)

OS_days

Overall survival time in days

OS_status

Overall survival status (0=alive, 1=dead)

Mutation_Load

Tumor mutation burden

Neo_antigen_Load

Neoantigen load

CD_8_T_effector

CD8+ T effector signature score

Immune_Checkpoint

Immune checkpoint signature score

Pan_F_TBRs

Pan-fibroblast TGF-\beta response signature

Mismatch_Repair

Mismatch repair status or signature

TumorPurity

Estimated tumor purity

Source

IMvigor210 clinical trial (NCT02108652)

References

Mariathasan S et al. TGF\beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544-548 (2018). doi:10.1038/nature25501

Examples

data(imvigor210_pdata)
head(imvigor210_pdata)

IOBR documentation built on May 30, 2026, 5:07 p.m.